Aparna Vema

Employment

• PozeSCAF Discovery Solutions Senior Director
  2023 - Present
• University of Hyderabad Scientist
  2020 - 2023
• Sree Chaitanya Institute of Pharmaceutical Sciences Principal
  2009 - 2015
• Uppsala University Post Doctoral Fellow
  2007 - 2009
• Nalanda College of Pharmacy Lecturer
  2000 - 2001

Education

• University of Hyderabad Ph.D.
  2003 - 2007
• National Institute of Pharmaceutical Education and Research M.S.(Pharm.)
  1998 - 2000
• National College of Pharmacy B.Pharmacy
  1994 - 1998

Projects & Funding

Projects & funding information is unavailable.

Publications (15)

• Identification of novel HDAC8 selective inhibitors through ligand and structure based studies: Exploiting the acetate release channel differences among class I isoforms
  Arabian Journal of Chemistry 2022 DOI: 10.1016/j.arabjc.2022.103863
  +Save
• Discovery of Novel Dihydropyrimidine and hydroxamic acid hybrids as potent Helicobacter pylori Urease inhibitors
  Bioorganic Chemistry 2021 DOI: 10.1016/j.bioorg.2021.105010
  +Save
• Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation
  Scientific Reports 2019 DOI: 10.1038/s41598-019-53376-y
  +Save
• Structure Activity Relationship, Drug Likeness and Evaluation of Antioxidant Activity of Some Mannich Bases of Dihydropyrimidinones
  Asian Journal of Chemistry 2019 DOI: 10.14233/ajchem.2019.22008
  +Save
• A combined pharmacophore modeling, 3D QSAR, virtual screening, molecular docking, and ADME studies to identify potential HDAC8 inhibitors
  Medicinal Chemistry Research 2016 DOI: 10.1007/s00044-016-1652-5
  +Save
• P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
  Bioorganic & medicinal chemistry 2011 DOI: 10.1016/j.bmc.2011.06.064
  +Save
• Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
  Bioorganic & medicinal chemistry 2010 DOI: 10.1016/j.bmc.2010.06.101
  +Save
• Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
  Bioorganic & medicinal chemistry 2010 DOI: 10.1016/j.bmc.2010.05.027
  +Save
• Structure–activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V
  Antiviral Therapy 2010 DOI: 10.3851/imp1655
  +Save
• Insights into ligand selectivity in nitric oxide synthase isoforms: a molecular dynamics study.
  Journal of molecular graphics & modelling 2007 DOI: 10.1016/j.jmgm.2007.02.003
  +Save